Nitrous oxide key to low IOP

A new ocular anti-hypertensive agent has been shown to be more effective at lowering average diurnal intraocular pressure than the established prostaglandin analogue drug latanoprost, in a phase 2b study.

In results released at this year's ARVO conference, the nitric-oxide donating prostaglandin F2-analogue drug latanoprostene bunod also showed more successful responders among the sample trialled. Response success was defined as achieving 18mmHg or less IOP. Intervention in nitrous oxide levels appears to show great potential as a mechanism for influencing IOP in glaucoma treatment.